{"id":"W3012254007","doi":"10.1177/2055217320911939","title":"An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability","year":2020,"lang":"en","type":"article","venue":"Multiple Sclerosis Journal - Experimental Translational and Clinical","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Allergan; EMD Serono; Genentech; MedDay Pharmaceuticals; Sanofi; Bayer HealthCare; Chugai Pharmaceutical; Mallinckrodt Pharmaceuticals; Acorda Therapeutics; Mylan; TG Therapeutics; Sanofi Genzyme; F. Hoffmann-La Roche; Teva Pharmaceutical Industries; Biogen; Celgene; University of Texas Health Science Center at Houston","keywords":"Ocrelizumab; Medicine; Expanded Disability Status Scale; Multiple sclerosis; Placebo; Internal medicine; Interferon beta-1a; Oncology; Clinical trial; Physical therapy; Immunology; Pathology; Rituximab; Alternative medicine","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005891066,0.001095133,0.001452742,0.0006078294,0.0003091735,0.0005606833,0.0005074324,0.0006119679,0.002747795],"category_scores_gemma":[0.007089585,0.0002621656,0.003442541,0.0004546926,0.0005491276,0.0004694479,0.0005198439,0.0007194226,0.0002324746],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005721723,"about_ca_system_score_gemma":0.0009299341,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002038761,"about_ca_topic_score_gemma":0.0003780671,"domain_scores_codex":[0.995912,0.002935036,0.0002376135,0.0004122084,0.0002574114,0.0002458323],"domain_scores_gemma":[0.9929175,0.004594681,0.001257117,0.0005504003,0.000305578,0.0003746459],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.8856807,0.005870607,0.05936142,0.0015903,0.01214508,0.0005159947,0.0002605291,0.001670765,0.00760802,0.0003640361,0.00106162,0.023871],"study_design_scores_gemma":[0.1862143,0.5440745,0.232672,0.0002138609,0.01854638,0.001119792,0.0003650467,0.004053573,0.00656607,0.0009541744,0.005120779,0.00009957612],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9953151,0.001858891,0.0005381769,0.0001077268,0.00002599293,0.0007108733,0.0006451535,0.0000173087,0.0007808398],"genre_scores_gemma":[0.9971693,0.0002315586,0.0007405637,0.0001028766,0.00004878542,0.000672956,0.0007306244,0.000005330357,0.0002980972],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005891066,"threshold_uncertainty_score":0.03115535,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1264345621215076,"score_gpt":0.345705107309352,"score_spread":0.2192705451878444,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}